Free tool
Upcoming earnings calendar
See who reports in the next 30, 60 or 90 days, from the ~22,000 stocks we cover — filter by cap, sector, theme or market, then open any ticker for the full analysis.
See who reports in the next 30, 60 or 90 days, from the ~22,000 stocks we cover — filter by cap, sector, theme or market, then open any ticker for the full analysis.
See who reports in the Americas in the next 90 days, from the ~22,000 stocks we cover — filter by cap, sector, theme or market, then open any ticker for the full analysis.
115 companies reporting in the next 90 days. Clear filters
Data as of Aug 27, 2026 · updates nightly, Mon–Sat
| Ticker | Company | Theme | Market cap (USD) | 1M return | |
|---|---|---|---|---|---|
| Monday, Aug 31 · in 4 days · 1 company | |||||
| BLRX | BioLineRx Ltd. | Oncology | $11.79M | −3.91% | |
| Wednesday, Sep 2 · in 6 days · 1 company | |||||
| IMMP | Immutep Limited | Oncology | $56.00M | −2.56% | |
| Wednesday, Sep 9 · in 13 days · 1 company | |||||
| ANIX | Anixa Biosciences, Inc. | Oncology | $122.65M | +2.41% | |
| Thursday, Sep 17 · in 21 days · 1 company | |||||
| IPHA | Innate Pharma S.A. | Oncology | |||
Price chart, technicals, money flow, fundamentals and an AI-written read — one page per stock. Looking for a name that isn't listed? Jump straight to it:
| $253.56M |
| +28.57% |
| Monday, Sep 28 · in 32 days · 1 company | |||||
| LNAI | Lunai Bioworks Inc. | Oncology | $9.97M | −1.79% | |
| Tuesday, Sep 29 · in 33 days · 1 company | |||||
| NBTX | Nanobiotix S.A. | Oncology | $2.26B | +17.66% | |
| Thursday, Oct 8 · in 42 days · 1 company | |||||
| NRIX | Nurix Therapeutics, Inc. | Oncology | $2.77B | +10.60% | |
| Monday, Oct 19 · in 53 days · 1 company | |||||
| SMMT | Summit Therapeutics Inc. | Oncology | $11.35B | +13.39% | |
| Tuesday, Oct 27 · in 61 days · 3 companies | |||||
| INCY | Incyte Corporation | Oncology | $25.97B | −1.39% | |
| EXEL | Exelixis, Inc. | Oncology | $14.05B | −0.73% | |
| RCUS | Arcus Biosciences, Inc. | Oncology | $3.92B | +13.72% | |
| Thursday, Oct 29 · in 63 days · 5 companies | |||||
| MRK | Merck & Co., Inc. | Oncology | $377.72B | +16.14% | |
| BMY | Bristol-Myers Squibb Company | Oncology | $138.03B | +6.24% | |
| NVCR | NovoCure Limited | Oncology | $2.08B | +9.69% | |
| BCYC | Bicycle Therapeutics plc | Oncology | $304.03M | +10.53% | |
| HBP.TO | Helix BioPharma Corp. | Oncology | $106.76M | +33.79% | |
| Friday, Oct 30 · in 64 days · 2 companies | |||||
| AZN | AstraZeneca PLC | Oncology | $263.12B | −3.60% | |
| HOWL | Werewolf Therapeutics, Inc. | Oncology | $48.05M | +120.22% | |
| Monday, Nov 2 · in 67 days · 3 companies | |||||
| NUVB | Nuvation Bio Inc. | Oncology | $2.44B | +4.04% | |
| SNDX | Syndax Pharmaceuticals, Inc. | Oncology | $1.77B | +2.34% | |
| PYXS | Pyxis Oncology, Inc. | Oncology | $278.58M | +14.78% | |
| Tuesday, Nov 3 · in 68 days · 10 companies | |||||
| BNTX | BioNTech SE | Oncology | $28.28B | +21.75% | |
| COGT | Cogent Biosciences, Inc. | Oncology | $6.39B | −9.71% | |
| CRVS | Corvus Pharmaceuticals, Inc. | Oncology | $1.22B | +10.67% | |
| KURA | Kura Oncology, Inc. | Oncology | $1.16B | +40.28% | |
| RIGL | Rigel Pharmaceuticals, Inc. | Oncology | $864.97M | +20.73% | |
| NVCT | Nuvectis Pharma, Inc. | Oncology | $816.10M | +26.14% | |
| VSTM | Verastem, Inc. | Oncology | $641.19M | +18.62% | |
| DCTH | Delcath Systems, Inc. | Oncology | $569.06M | +41.99% | |
| HRTX | Heron Therapeutics, Inc. | Oncology | $59.27M | −36.29% | |
| KPTI | Karyopharm Therapeutics Inc. Common Stock | Oncology | $44.46M | −72.36% | |
| Wednesday, Nov 4 · in 69 days · 6 companies | |||||
| RVMD | Revolution Medicines, Inc. | Oncology | $46.18B | +17.18% | |
| TNGX | Tango Therapeutics, Inc. | Oncology | $4.29B | −4.43% | |
| XNCR | Xencor, Inc. Common Stock | Oncology | $2.11B | +42.41% | |
| VIR | Vir Biotechnology, Inc. | Oncology | $1.87B | +25.20% | |
| GERN | Geron Corporation | Oncology | $995.83M | +5.52% | |
| ARVN | Arvinas, Inc. | Oncology | $609.40M | +13.66% | |
| Thursday, Nov 5 · in 70 days · 28 companies | |||||
| ONC | BeOne Medicines AG | Oncology | $42.58B | +13.72% | |
| GMAB | Genmab A/S | Oncology | $21.42B | +16.38% | |
| LNTH | Lantheus Holdings, Inc. | Oncology | $6.58B | −1.77% | |
| RLAY | Relay Therapeutics, Inc. | Oncology | $4.26B | +6.40% | |
| IMNM | Immunome, Inc. | Oncology | $3.34B | +23.82% | |
| ZLAB | Zai Lab Limited | Oncology | $2.92B | +39.80% | |
| URGN | UroGen Pharma Ltd. | Oncology | $2.25B | +12.38% | |
| ZYME | Zymeworks Inc. | Oncology | $2.10B | +29.61% | |
| IMCR | Immunocore Holdings plc | Oncology | $1.93B | +10.77% | |
| DMRA | Damora Therapeutics, Inc. | Oncology | $1.89B | +3.30% | |
| REPL | Replimune Group, Inc. | Oncology | $1.50B | +196.82% | |
| CGEM | Cullinan Therapeutics, Inc. | Oncology | $1.48B | +30.80% | |
| GLUE | Monte Rosa Therapeutics, Inc. | Oncology | $1.23B | −34.75% | |
| JANX | Janux Therapeutics, Inc. | Oncology | $1.15B | +25.93% | |
| CTMX | CytomX Therapeutics, Inc. | Oncology | $723.43M | +3.11% | |
| GUD.TO | Knight Therapeutics Inc. | Oncology | $690.78M | −0.81% | |
| CCCC | C4 Therapeutics, Inc. | Oncology | $521.63M | +19.44% | |
| PBYI | Puma Biotechnology, Inc. | Oncology | $472.84M | +14.93% | |
| CMPX | Compass Therapeutics, Inc. | Oncology | $437.61M | +19.12% | |
| FHTX | Foghorn Therapeutics Inc. | Oncology | $397.29M | +30.41% | |
| AGEN | Agenus Inc. | Oncology | $371.33M | +25.00% | |
| WHWK | Whitehawk Therapeutics, Inc. | Oncology | $275.92M | +31.52% | |
| CHRS | Coherus Oncology, Inc. | Oncology | $224.03M | +0.69% | |
| BDTX | Black Diamond Therapeutics, Inc. | Oncology | $130.42M | +28.98% | |
| PLRX | Pliant Therapeutics, Inc. | Oncology | $73.69M | +8.41% | |
| TPST | Tempest Therapeutics, Inc. | Oncology | $17.86M | +24.00% | |
| LSTA | Lisata Therapeutics, Inc. | Oncology | $15.68M | +50.00% | |
| CRIS | Curis, Inc. | Oncology | $3.86M | −68.12% | |
| Friday, Nov 6 · in 71 days · 1 company | |||||
| ALXO | ALX Oncology Holdings Inc. | Oncology | $273.79M | −0.50% | |
| Monday, Nov 9 · in 74 days · 7 companies | |||||
| CGON | CG Oncology, Inc. | Oncology | $6.95B | +7.99% | |
| IDYA | IDEAYA Biosciences, Inc. | Oncology | $4.01B | +14.99% | |
| OLMA | Olema Pharmaceuticals, Inc. | Oncology | $949.35M | −6.63% | |
| TOI | Starling Oncology Inc | Oncology | $512.91M | +25.25% | |
| CATX | Perspective Therapeutics, Inc. | Oncology | $360.72M | +10.10% | |
| CGEN | Compugen Ltd. | Oncology | $271.86M | +25.66% | |
| KYNB | Kyntra Bio, Inc. | Oncology | $32.82M | +16.20% | |
| Tuesday, Nov 10 · in 75 days · 4 companies | |||||
| BCAX | Bicara Therapeutics Inc. | Oncology | $1.64B | −8.00% | |
| ZNTL | Zentalis Pharmaceuticals, Inc. | Oncology | $368.27M | −15.80% | |
| TARA | Protara Therapeutics, Inc. | Oncology | $231.06M | −0.76% | |
| ADCT | ADC Therapeutics SA | Oncology | $134.05M | −5.41% | |
| Wednesday, Nov 11 · in 76 days · 9 companies | |||||
| ERAS | Erasca, Inc. | Oncology | $6.70B | +5.45% | |
| CELC | Celcuity Inc. | Oncology | $4.65B | +15.30% | |
| ELVN | Enliven Therapeutics, Inc. | Oncology | $4.46B | +13.22% | |
| SLS | SELLAS Life Sciences Group, Inc. | Oncology | $2.77B | +36.08% | |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | Oncology | $751.23M | +7.80% | |
| PRLD | Prelude Therapeutics Incorporated | Oncology | $522.47M | +41.38% | |
| IMRX | Immuneering Corporation | Oncology | $333.19M | +21.46% | |
| LTRN | Lantern Pharma Inc. | Oncology | $27.87M | −16.15% | |
| BFRI | Biofrontera Inc. | Oncology | $22.72M | +37.84% | |
| Thursday, Nov 12 · in 77 days · 14 companies | |||||
| AKTS | Aktis Oncology, Inc. | Oncology | $1.47B | +15.41% | |
| ORIC | ORIC Pharmaceuticals, Inc. | Oncology | $1.44B | +16.79% | |
| CADL | Candel Therapeutics, Inc. | Oncology | $1.02B | +37.19% | |
| AURA | Aura Biosciences, Inc. | Oncology | $801.64M | +9.65% | |
| MNPR | Monopar Therapeutics Inc. | Oncology | $763.31M | +4.24% | |
| EIKN | Eikon Therapeutics, Inc. | Oncology | $679.77M | +26.24% | |
| SGMT | Sagimet Biosciences Inc. | Oncology | $675.04M | +49.38% | |
| RLMD | Relmada Therapeutics, Inc. | Oncology | $485.35M | −13.00% | |
| FRX.TO | Fennec Pharmaceuticals Inc. | Oncology | $429.52M | +21.86% | |
| FENC | Fennec Pharmaceuticals Inc. | Oncology | $426.77M | +22.43% | |
| GLSI | Greenwich LifeSciences, Inc. | Oncology | $267.58M | +35.54% | |
| MGNX | MacroGenics, Inc. Common Stock | Oncology | $257.35M | +4.94% | |
| NTHI | NeOnc Technologies Holdings, Inc. | Oncology | $122.16M | +30.66% | |
| CRDF | Cardiff Oncology, Inc. | Oncology | $76.56M | +20.01% | |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India). Reporting dates are public estimates and can shift.